Compare FDP & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | AAPG |
|---|---|---|
| Founded | 1886 | 2009 |
| Country | Cayman Islands | China |
| Employees | N/A | 767 |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 1999 | N/A |
| Metric | FDP | AAPG |
|---|---|---|
| Price | $41.11 | $22.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $48.40 |
| AVG Volume (30 Days) | ★ 187.0K | 2.1K |
| Earning Date | 05-05-2026 | 05-20-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $4,322,300,000.00 | N/A |
| Revenue This Year | N/A | $290.34 |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | $22.37 | ★ N/A |
| Revenue Growth | ★ 0.98 | N/A |
| 52 Week Low | $31.85 | $20.11 |
| 52 Week High | $43.58 | $48.45 |
| Indicator | FDP | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 42.19 |
| Support Level | $40.04 | $21.20 |
| Resistance Level | $43.06 | $25.23 |
| Average True Range (ATR) | 0.89 | 0.38 |
| MACD | -0.03 | -0.40 |
| Stochastic Oscillator | 35.96 | 12.69 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.